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Abstract: Management of male infertility is always a difﬁ  cult task, and the pathologic process 
is often poorly understood. Even though modern assisted reproduction techniques (ART) can 
help overcome severe male factor infertility, the application of these methods in all infertile 
couples would deﬁ  nitely represent over-treatment. Several conditions can interfere with sper-
matogenesis and reduce sperm quality and production. A careful diagnostic work-up is neces-
sary before any andrological treatment can be initiated so that adequate treatment options can 
be selected for individual patients. Most hormonal imbalances can be readily identiﬁ  ed and 
successfully treated nonsurgically. However, the treatment of men with unexplained idiopathic 
infertility remains a challenge. In the absence of a correctable etiology, patients are managed 
with either empirical medical therapy or ART. Empiric medical therapy continues as a viable 
option. However, physicians and patients must understand that the success rates with any of 
the pharmacological therapies remain suboptimal.
Keywords: male infertility, oligospermia, drug therapy
Introduction
Approximately 10% of all couples seek fertility assessment. Infertility services are 
increasingly being utilized due to the later age of ﬁ  rst pregnancy and associated reduc-
tion in female fertility. Assisted reproductive techniques remain an effective option for 
infertile couples. However, the cost is considerable, and there is a small but deﬁ  nite risk 
of ovarian hyperstimulation as well as fetal and maternal consequences associated with 
multiple gestation and developmental defects. In half of infertility cases, a male factor 
is involved. Thus, identifying the pathology and treating the male may allow couples to 
regain fertility and conceive through natural intercourse. The goal of speciﬁ  c medical 
management of infertility is to diagnose reversible causes of infertility and treat them 
with appropriate medications to achieve seminal improvement and pregnancy.
In spite of advancements in the diagnostic work-up of infertile men, up to 25% 
of patients exhibit abnormal semen analyses for which no etiology can be identiﬁ  ed 
(Greenberg et al 1978). This condition is referred to as idiopathic male infertility, 
and nonspeciﬁ  c treatments are usually applied that are based on theoretical concepts. 
Empiric therapies may also be used for men with a known but otherwise untreatable 
cause of infertility or for patients with identiﬁ  ed and potentially treatable causes of 
infertility but for whom previous treatments failed. A variety of empiric medical 
therapies have been recommended to treat these patients. However, with few excep-
tions, none of these therapies has been shown to be effective in repeated controlled 
randomized studies. Such studies are difﬁ  cult to conduct since effective treatments 
are available, and few infertile couples are willing to delay treatment.
When empiric pharmacologic therapy is going to be used, treatment should last 
at least 3 to 6 months to incorporate a full 74-day spermatogenic cycle. The infertile 
couple should be advised of the inconsistent response to therapy and the low conception Biologics: Targets & Therapy 2007:1(3) 260
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rate that may follow when compared with the results of ART. 
Lack of a signiﬁ  cant improvement in seminal parameters or 
no pregnancy after at least two spermatogenic cycles may 
be an indication to proceed with ART.
Current medical treatment options for male infertility are 
discussed in this article. As stated earlier, most of the recom-
mendations are not based on controlled studies.
Speciﬁ  c treatment
Hypogonadotropic hypogonadism
Common causes of hypogonadotropic hypogonadism (HGH) 
include Kallmann’s syndrome, pituitary tumors, pituitary 
trauma and anabolic steroid use. HGH is the cause of infertil-
ity in a small percentage of patients; the disorder can be clas-
siﬁ  ed as congenital or acquired (Liu and Handelsman 2003). 
One example of congenital HGH is Kallmann syndrome, 
which is a malformation of the midline cranial structures 
(Cunningham and Lipshultz 1986). In this syndrome, the 
defect is at the level of the hypothalamic secretion of gonado-
tropin-releasing hormone (GnRH) and may be associated 
with other congenital anomalies such as anosmia, deafness, 
cleft palate and renal anomalies. Acquired causes of HGH 
include pituitary tumors, pituitary trauma, panhypopituita-
rism and anabolic steroid use.
The initial evaluation of patients with suspected HGH 
may include a pituitary MRI to rule out a pituitary tumor 
(Gilbaugh and Lipshultz 1994). Pituitary tumors can cause 
local destruction of the anterior pituitary. A serum prolactin 
level should be measured, and hyperprolactinemia must be 
ruled out and treated before gonadotropin replacement.
In patients with acquired HGH, normal spermatogen-
esis can usually be restored by treatment with exogenous 
gonadotropins or GnRH. Human chorionic gonadotropin 
(hCG) therapy, which contains LH-like activity, is the most 
commonly used treatment in HGH for economic and com-
pliance reasons (Conte et al 1990; Shin and Honig 2002). 
Human menopausal gonadotropin (hMG), which contains 
both FSH and LH, also has been used for replacement 
therapy in these patients. Normally, the treatment involves 
the subcutaneous administration of hCG 1500–3000 IU 
three times per week (March and Isidori 2002). How-
ever, congenital causes frequently require the addition of 
follicle-stimulating hormone (FSH). In these cases, after 
approximately 3 months of hCG therapy, intramuscular 
injections of FSH at dose of 37.5 to 75 IU are added 
three times per week. FSH is available in a recombinant 
form as well as in a highly puriﬁ  ed urinary form. Serum 
testosterone levels and seminal analysis are followed 
during treatment. On average, it takes approximately 6 to 
9 months before spermatozoa appear in the ejaculate (Haidl 
2002). However, this period can be much longer (March and 
Isidori 2002). Once sperm concentrations reach satisfactory 
levels, FSH can be suspended, and spermatogenesis may 
be maintained with hCG alone (Siddiq and Sigman 2002). 
Although patients usually present with abnormal seminal 
parameters, many of them can initiate a pregnancy even 
when their sperm concentration is well below the conven-
tional lower limit of 20 × 106/ml (Burris et al 1988). Also, 
hormone replacement therapy is more cost-effective than 
sperm retrieval/intracytoplasmic sperm injection (ICSI) in 
these patients (Shin and Honig 2002).
Patients who do not respond after hCG/FSH combina-
tion therapy may respond to GnRH via either intravenous 
or subcutaneous injections given in a pulsatile fashion 
with a portable infusion pump. Pulsatile GnRH is an effec-
tive treatment of non-pituitary gonadotrophin deﬁ  ciency, 
both for inducing androgenization and spermatogenesis 
(Mortimer et al 1974; Crowley et al 1985). Normally, 
GnRH 5 to 20 mg/120 min is administered subcutaneously 
through an indwelling butterﬂ  y needle (Liu and Handelsman 
2003). Intranasal GnRH can maintain previously induced 
spermatogenesis (Klingmuller and Schweikert 1985). 
However, the need for a 2-hour dosing regimen makes this 
clinically unfeasible. Nevertheless, pulsatile GnRH therapy 
depends on a intact pituitary gonadotropin response to the 
exogenous GnRH (Chuang and Howards 1998). Crowley 
and Whitcomb reported that eight of nine patients with 
idiopathic HGH desiring induction of fertility were able 
to father a child with the use of pulsatile GnRH therapy 
(Crowley and Whitcomb 1990).
Hyperprolactinemia
Hyperprolactinemia is a form of HGH caused by excessive 
prolactin secretion (Burrows et al 2002). An excess of prolac-
tin inhibits the hypothalamic secretion of GnRH and has been 
implicated as a cause of reproductive and sexual dysfunction. 
Routine screening of infertile men for hyperprolactinemia has 
not been shown to be useful (Eggert-Kruse et al 1991). The 
condition may be caused by a pituitary tumor (macroadenoma 
or microadenoma), hypothyroidism, stress, medications 
such as phenothiazines, tricyclic antidepressants and some 
antihypertensives, medical illness, and idiopathic factors 
(Siddiq and Sigman 2002). The most common causes of 
hyperprolactinemia are prolactin-secreting microadenomas 
(10mm) and prolactin-secreting macroadenomas (10mm) 
(Jane and Laws 2001).Biologics: Targets & Therapy 2007:1(3) 261
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The level of prolactin elevation provides insight into the 
type of pathology. Prolactin levels greater than 250 ng/ml, 
between 100 and 250 ng/ml, between 25 and 100 ng/ml, and 
from 0 to 25 ng/ml most commonly correspond to macroad-
enoma, microadenoma, pituitary stalk compression and normal 
levels, respectively (Burrows et al 2002). Generally, in patients 
with prolactin-secreting pituitary adenomas, gonadotropin and 
testosterone levels are suppressed whereas prolactin levels are 
elevated. All patients with hyperprolactinemia should be evalu-
ated with a pituitary MRI with gadolinium contrast to rule out a 
pituitary tumor. An elevation in peripheral prolactin should be 
followed with repeat testing because prolactin levels can vary 
widely throughout the day and with physical activity.
Treatment of hyperprolactinemia depends on the cause. 
Treatment of hypothyroidism or cessation of source medi-
cations usually brings serum prolactin levels back into the 
normal range. Although surgery and radiation therapy have 
been used in the past to treat patients with prolactin-secreting 
pituitary tumors, the vast majority of patients with idiopathic 
hyperprolactinemia or pituitary adenomas do not require 
surgery, and medical therapy is the initial treatment of 
choice (Molitch 1999). However, patients with macroad-
enomas generally require surgical therapy. Bromocriptine, a 
dopaminergic antagonist, can signiﬁ  cantly reduce the serum 
prolactin levels in oligospermic men with hyperprolactinemia 
and increase sperm counts to a level that may result in preg-
nancy (Chuang and Howards 1998). Doses range from 2.5 
to 7.5 mg per day and are given two to four times per day to 
avoid gastrointestinal side effects. Doses can be increased 
with time (Mancini et al 1984). In most cases, the serum 
prolactin levels return to normal.
Cabergoline is a new long-acting dopamine agonist that 
is effective and well tolerated in patients with pathologi-
cal hyperprolactinemia. Cabergoline has been shown to be 
as effective as bromocriptine in lowering prolactin levels 
and reducing tumor size (Verhelst et al 1999). Moreover, 
cabergoline has the advantage of fewer side effects than 
bromocriptine and requires less frequent dosing. The median 
dose of cabergoline at the start of therapy is 1.0 mg/week, 
but once prolactin secretion is adequately controlled, the 
dose can be reduced to 0.5 mg/week, which further reduces 
therapy costs (Verhelst et al 1999). Selected patients with 
idiopathic hyperprolactinemia can be treated with medica-
tion as well, which may be withdrawn yearly to assess for 
persistent hyperprolactinemia (Dollar and Blackwell 1986; 
Wang et al 1987) Transsphenoidal surgery remains an option, 
especially for patients with microadenomas, when medical 
therapy is ineffective (Molitch 1999).
Immunologic infertility
An immunologic basis for some cases of infertility has been 
identiﬁ  ed in a signiﬁ  cant number of infertile men, suggesting 
that antisperm antibodies (ASA) may have a harmful effect in 
fertilization (Rumke and Hellinga 1959). Immunologic infer-
tility is characterized by the presence of antibodies against 
spermatozoa in the serum and/or in the seminal plasma or on 
the sperm surface. The presence of multiple ASA can lead 
to the immobilization and/or agglutination of spermatozoa, 
which blocks sperm-egg interaction. They can also prevent 
implantation, and/or arrest embryo development (Haas 1986; 
Koide et al 2000). Common causes of ASA include previous 
genital tract infection, testicular biopsy, testicular trauma, 
testicular torsion and vasectomy (Broderick et al 1989; Koide 
et al 2000; Arap et al 2007).
The real signiﬁ  cance of ASA in infertile men is contro-
versial and currently, there are no standardized treatment 
regimens (Marshburn and Kutteh 1994). Oral corticoids 
are commonly used to suppress antibody production, but to 
date, no double-blind, randomized trial has conﬁ  rmed their 
efﬁ  cacy. Studies following different protocols report preg-
nancy rates between 0 to 44% (De Almeida and Souﬁ  r 1977; 
Shulman and Shulman 1982; Hendry et al 1986; Dondero 
et al 1993). Studies in which treatment was continued for 
more than 3 months reported a signiﬁ  cant increase in the 
number of pregnancies amongst those receiving predniso-
lone compared with placebo (Hendry et al 1990; Omu et al 
1996). However, a meta-analysis showed no signiﬁ  cant 
improvement in pregnancy rates with prednisolone therapy 
(Kamischke and Nieschlag 1999).
ICSI is considered to be the treatment of choice for 
patients with severe sperm autoimmunity (Check et al 2000). 
Clarke et al showed no signiﬁ  cant differences in fertiliza-
tion rates (62% versus 58%) or clinical pregnancy rates 
(19% versus 12%) between sperm antibody-positive and 
sperm antibody-negative patient groups (Clarke et al 1997). 
However, recently, higher fertilization rates during in vitro 
fertilization (IVF) were reported in patients with antisperm 
antibodies and immunosuppressive therapy compared to 
IVF alone (Shin et al 1998; Haidl 2002). Thus, treatment 
of antisperm antibodies using corticosteroids should not be 
prescribed routinely, but it can be considered in patients with 
antisperm antibodies and earlier failed fertilization during   
IVF or ICSI.
Genital tract infection
The prevalence of leukocytospermia (106 WBC/mL semen) 
among male infertility patients is approximately 10%–20% Biologics: Targets & Therapy 2007:1(3) 262
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(Wolff 1995). Under wet mount microscopy, both leukocytes 
and immature germ cells have a similar appearance and are 
properly termed “round cells.” Although many laboratories 
improperly report all round cells as white blood cells, the 
clinician must make sure that the two types of cells are differ-
entiated. Leukocytes are difﬁ  cult to differentiate from imma-
ture germ cells without use of traditional cytologic staining 
and immunohisthochemical techniques (Wolff and Anderson 
1988). The World Health Organization considers leukocy-
tospermia to be a condition in which leukocyte levels are 
equal to or exceed 1 × 106/mL (WHO 1999). However, recent 
studies reported that leukocyte counts below 1 × 106/mL were 
signiﬁ  cantly correlated with production of seminal reactive 
oxygen species (ROS) as well as decreased sperm DNA 
integrity (Sharma et al 2001; Henkel et al 2003; Henkel et al 
2005; Athayde et al 2007). All men with elevated seminal 
white blood cell levels (>1 × 106/mL) should be evaluated for 
a genital tract infection or inﬂ  ammation, and a semen culture 
should be performed. Unexpectedly, approximately 80% of 
leukocytospermic samples are microbiologically negative 
(Jennings et al 1986; Wolff 1995).
The signiﬁ  cance of WBC in semen is controversial. 
Most studies found that leukocytospermia is associated with 
decreased sperm motility and fertilization capacity (Berger 
et al 1982; Maruyama et al 1985; Wolff et al 1990; Aitken 
et al 1992; Aitken et al 1994). However, El-Demiry et al 
reported no association between standard seminal parameters 
and leukocyte concentration in human semen (El-Demiry 
et al 1986). This discrepancy may be due to the fact that dif-
ferent techniques were used to determine leukocyte concen-
tration in semen. In addition, the studies differed in regards 
to the lower leukocyte concentration responsible for sperm 
damage (Shekarriz et al 1995; Henkel et al 2005; Athayde 
et al 2007). Infections located in the testis and epididymis 
produce ROS that are particularly harmful to sperm due to 
their lack of a pro-oxidant defense system.
The most commonly found gram-positive and gram-
negative bacteria are Streptococcus fecalis and Escherichia 
coli, respectively (March and Isidori 2002). Also, Chlamydia 
trachomatis and Ureaplasma urealyticum are often involved. 
Once the responsible microorganism has been identiﬁ  ed, 
antibiotic therapy is initiated. However, culture-negative 
patients should be treated with anti-inﬂ  ammatory therapy 
and frequent ejaculation because empiric antibiotic therapy 
generally provides no beneﬁ  t and may be harmful (Comhaire 
et al 1986; Yanushpolsky et al 1995). In cases of refractory 
leukocytospermia, sperm washing can be performed before 
intrauterine insemination to remove the white cells.
According to the microbiological ﬁ  ndings the following 
agents can be used as treatment: Doxycycline 200 mg/day, 
tetracycline 1.5 to 2 g/day, ﬂ  uoroquinolones (oﬂ  oxacin, 
norﬂ  oxacin, ciproﬂ  oxacin, levoﬂ  oxacin) 0.5 to 1 g/day, 
cotrimoxazole (sulfamethoxazole 800 mg, trimethoprim 
160 mg) or macrolides, eg, erythromycin 1.5 to 2 g/day. 
These drugs are administered for 2 to 3 weeks (Haidl and 
Schill 1991). The objectives of treatment are to reduce or 
eradicate microorganisms in prostatic secretions and semen, 
normalize inﬂ  ammatory parameters such as leukocyte levels 
and biochemical markers such as granulocyte elastase, and 
improve sperm parameters (Weidner et al 1999). Although 
antibacterial therapy can reduce inﬂ  ammatory inﬂ  uences 
when administered in patients with genital tract infection, 
there are no available studies on this subject that show 
improved pregnancy rates (Weidner 1999).
Disorders of ejaculation
Ejaculatory dysfunction includes a variety of disorders 
with individualized treatments. Although this is a relatively 
unusual cause of male infertility, its represents an interesting 
challenge to the treating physician (Schuster and Ohl 2002). 
Ejaculatory dysfunction should be suspected in any patient 
with low-volume (1.0 ml) or absent ejaculate and should be 
distinguished from anorgasmia. Retrograde ejaculation can 
be deﬁ  ned as the abnormal backward ﬂ  ow of semen into the 
bladder with ejaculation; the etiology may be anatomic, neu-
rogenic, pharmacologic or idiopathic. Pharmacologic agents 
implicated in retrograde ejaculation include neuroleptics, 
tricyclic antidepressants, alpha-blockers used in the treatment 
of prostatism and certain antihypertensives (Hendry 1998; 
Debruyne 2000; Schuster and Ohl 2002). The diagnosis of 
retrograde ejaculation is made by examining the post-ejaculate 
urine for sperm. Although exact criteria have not been estab-
lished for a positive post-ejaculate urinalysis, the ﬁ  nding of 
greater than 10 to 15 sperm per high-power ﬁ  eld conﬁ  rms the 
presence of retrograde ejaculation. In contrast, sperm will not 
be present in the urine of a patient with failure of emission, 
which must be diagnosed by clinical suspicion.
In the treatment of retrograde ejaculation, an initial trial 
of pharmacologic therapy is likely to be effective only in 
patients who do not have bladder neck abnormalities caused 
by surgery and in patients with failure of emission. The 
agents commonly utilized are alpha-adrenergic agonists such 
as ephedrine sulfate (25 to 50 mg q.i.d.), pseudoephedrine 
(60 mg q.i.d.), and imipramine (25 mg b.i.d.). The drugs 
may induce ejaculation secondary to an increase in the 
sympathetic tone of the internal sphincter and vas deferens. Biologics: Targets & Therapy 2007:1(3) 263
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Medical therapy for ejaculatory dysfunction is administered 
on a cyclical basis timed to the female partner’s ovulatory 
cycle. These medications are more effective if given for a 
period of at least 7 to 10 days before planned ejaculation, and 
tolerance may develop if they are administered continuously 
over several cycles. However, success is unlikely if no effect 
is observed within 2 weeks of treatment.
If medical therapy fails to restore normal ejaculation, 
spermatozoa may be retrieved from the postejaculatory urine 
before intrauterine insemination (Shangold et al 1990). Urine 
may damage spermatozoa because of its acidity, changes 
in osmolarity or contamination (Crich and Jequier 1978). 
Several methods to circumvent these problems have been 
proposed, including neutralizing the urine pH with oral bicar-
bonate (650 mg q.i.d. for 2 days) and hydrating the patient 
before sperm collection. Subsequent to ejaculation, urine 
is voided and processed for insemination. A more invasive 
method involves catheterizing the bladder with 30 cc of a 
buffered medium, which is discarded, and then instilling 
an additional 30 cc (Suominen et al 1991). After ejaculation, 
the patient voids or is catheterized to retrieve the specimen. 
This procedure is also timed to coincide with ovulation in 
the female partner.
Reactive oxygen species
Spermatozoa produce a small amount of ROS, which is nec-
essary for normal physiologic cell function such as capacita-
tion, hyperactivation and sperm-oocyte fusion (Sies 1993; 
Lewis et al 1995). Elevated ROS levels have been recognized 
as an independent marker of male factor infertility, irrespec-
tive of whether patients have normal or abnormal semen 
parameters (Agarwal et al 2006). Although the body employs 
a number of mechanisms to minimize ROS-induced damage, 
antioxidants in seminal plasma are the most important form 
of protection that sperm have against ROS insult (Agarwal 
and Prabakaran 2005). These ﬁ  ndings form the basis for the 
use of oral antioxidants as supplements to decrease oxidative 
stress and improve fertility.
The seminal plasma contains two different types of anti-
oxidants to minimize free radical-induced damage: enzymatic 
and non-enzymatic antioxidants. The antioxidant protection 
mechanisms comprise three levels of defense: prevention, 
interception and repair. Avoidance of ROS formation is 
the ﬁ  rst line of defense against an oxidative insult. As an 
example, the binding of metal ions, particularly iron and 
copper ions, prevents them from initiating a chain reaction 
(Sies 1993). Once transition metals become freely bound 
to ROS, they can generate more reactive oxidants, mainly 
OH- (Halliwell 1990). Free radicals have a predisposition 
toward activating a chain reaction. The interruption of this 
reaction to avoid further injury is the process of deactiva-
tion, which leads to a nonradical end product formation 
(Sies 1993). Alpha-tocopherol, a chain-breaking antioxidant, 
restrains lipid peroxidation by scavenging peroxyl (RO-) and 
alkoxyl (ROO-) radicals. The capability of α-tocopherol to 
preserve a steady-state rate of peroxyl radical decline in the 
plasma membrane depends on the recycling of α-tocopherol 
by external reducing agents such as ascorbate or thiols. In this 
way, α-tocopherol is capable of functioning as a free radical 
chain-breaking antioxidant even if its concentration is low 
(Buettner 1993). In most cases, free-radical induced damage 
can be repaired. However, spermatozoa plasma membranes 
contain large quantities of polyunsaturated fatty acids and 
their cytoplasm contains low concentrations of scaveng-
ing enzymes. As a result, spermatozoa are unable to repair 
damage caused by excessive ROS (Halliwell 1990; Buettner 
1993; Ochsendorf 1999; Irshad and Chaudhuri 2002). The 
pathological levels of ROS detected in the semen of infertile 
men are more likely to be caused by increased ROS produc-
tion than by reduced antioxidant capacity of the seminal 
plasma (Lewis et al 1995).
Current studies report the detection of increased 
ROS levels in the semen of 25% to 40% of infertile men 
(de Lamirande and Gagnon 1995; Padron et al 1997). Men 
classiﬁ  ed as having idiopathic infertility usually present with 
higher seminal ROS levels and lower antioxidant properties 
than healthy controls (Pasqualotto et al 2001). Given the 
major role that oxidative stress plays in the pathogenesis of 
male infertility, reducing seminal oxidative stress levels is 
necessary for natural as well as assisted reproductive tech-
nologies (Agarwal et al 2005). Various clinical trials have 
demonstrated the beneﬁ  cial effects of antioxidants in selected 
cases of male infertility (Lenzi et al 1993, 1994; Kodama 
et al 1997; Okada et al 1997; Comhaire et al 2000; Vicari and 
Calogero 2001), whereas others have failed to report similar 
beneﬁ  ts (Abel et al 1982; Kessopoulou et al 1995; Rolf et al 
1999). Pregnancy, the most relevant outcome parameter of 
fertility, was reported in only a few of these studies (Suleiman 
et al 1996; Comhaire et al 2000; Vicari and Calogero 2001; 
Vicari et al 2002; Lenzi et al 2003).
The majority of studies analyzed multiple antioxidant 
combinations, different doses and durations. Patient selection 
must also be considered in these studies since oxidative stress 
may not be the cause of male infertility in all selected patients. 
Recently, Agarwal et al (2004), in an extensive review of the 
literature, concluded that the studies suffer from the lack of Biologics: Targets & Therapy 2007:1(3) 264
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a placebo-controlled, double-blind design. Without such a 
study design, the effectiveness of antioxidant supplementa-
tion in infertile patients remains inconclusive.
Considering the etiology of infertility in various patients, 
antioxidants may not be effective (Agarwal et al 2004). 
Therapeutics directed against each speciﬁ  c etiological cause 
of elevated ROS should be attempted. Once the primary 
cause of infertility has been treated, or if no speciﬁ  c etiology 
can be identiﬁ  ed, patients may be advised to take antioxidant 
supplements.
Nonspeciﬁ  c treatment
Gonadotropin releasing hormone therapy
Hormone therapies manipulate the hypothalamic pituitary 
gonadal (HPG) axis in order to enhance sperm production. 
The axis is a complex, tightly regulated system of positive 
and negative feedback loops at numerous levels (Figure 1). 
However, hormonal manipulations of the normal HPG axis 
are not very successful due to homeostatic mechanisms 
that counteract the superimposed perturbation. A possible 
explanation for any beneﬁ  cial effects on spermatogenesis of 
empirical therapy may be due to the presence of a previous 
“subclinical endocrinopathy.”
Exogenous GnRH administration can increase gonado-
tropin production and, potentially, spermatogenesis. GnRH 
seems to be a more physiologic agent for increasing the 
pituitary’s production of FSH and LH, especially when 
it is administered in a pulsatile fashion in programmable, 
portable minipumps. Although GnRH therapy is effective 
in the treatment of patients with HGH, two controlled stud-
ies failed to ﬁ  nd efﬁ  cacy of pulsatile GnRH treatment for 
idiopathic oligo-astheno-teratozoospermia (Badenoch et al 
1988; Crottaz et al 1992). The pregnancy rates were similar 
to those of the controls with no seminal improvement. The 
lack of controlled studies indicating actual treatment beneﬁ  ts 
and the high cost of this therapy discourage its routine clinical 
use of GnRH for idiopathic oligozoospermia.
Gonadotropins
The two gonadotropins, FSH and LH, stimulate spermatogen-
esis and steroidogenesis, respectively. Exogenous gonado-
tropin treatments include the use of hCG and hMG. hCG is 
analogous to LH, and it stimulates the Leydig cell secretion 
of both testosterone and estradiol and inhibits FSH due to 
negative feed back. hMG has both LH and FSH activity. The 
reason for gonadotropin administration in idiopathic oligo-
zoospermia is based on observed efﬁ  cacy in the treatment 
of HGH. However, their effectiveness for treating normogo-
nadotropic oligospermia, either alone or in combination, is 
less clear (Siddiq and Sigman 2002).
Two randomized controlled studies have examined 
the effect of FSH stimulation alone using either puri-
ﬁ  ed hMG (Matorras et al 1997) or recombinant human 
FSH (Kamischke et al 1998). Neither reported improved 
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pregnancy rates with FSH, although one claimed a beneﬁ  t 
from a post-hoc analysis for a selected subpopulation 
(Matorras et al 1997). Numerous uncontrolled studies have 
been performed with hCG, but few have assessed the use 
of hMG in men with idiopathic oligospermia (Siddiq and 
Sigman 2002). These studies have revealed limited efﬁ  cacy 
(Siddiq and Sigman 2002), whereas the only available 
randomized double-blind, placebo-controlled, crossover 
study of hCG/hMG treatment of normogonadotropic 
men with idiopathic oligoasthenoteratospermia failed to 
demonstrate any beneﬁ  cial effect on semen parameters or 
pregnancy rates (Knuth et al 1987). Although the treatment 
is safe, the side effects include libido changes and acne. 
As with GnRH, these treatments are very expensive, and 
given the lack of convincing outcomes with controlled 
studies, this treatment is not routinely recommended 
in men without a demonstrable hormonal abnormality. 
Further research to examine its impact on pregnancy rates 
in carefully selected infertile men, possibly in combination 
with ART, is warranted (Liu and Handelsman 2003).
Antiestrogens
Antiestrogens are the most commonly used therapy for 
idiopathic infertility. The antiestrogens indirectly stimulate 
the secretion of FSH and LH by blocking estrogen and 
estosterone receptors in the hypothalamus, which increases 
the release of GnRH. Two non-steroidal antiestrogens, clo-
miphene and tamoxifen, have been evaluated for empirical 
treatment of idiopathic male infertility.
Clomiphene is a synthetic, nonsteroidal drug that is simi-
lar in structure to diethylstilbestrol. Although it has a mild 
estrogenic effect, it functions predominantly as an antiestro-
gen. Clomiphene citrate is normally prescribed in a 25-mg 
daily oral dose. Drug doses generally range from 12.5 to 400 
mg/day; however higher doses may cause down-regulation of 
the system (Heller et al 1969). Men treated with clomiphene 
citrate consistently demonstrate an elevation in serum FSH, 
LH and testosterone levels. As a result, serum gonadotro-
pins and testosterone must be monitored to ensure that the 
testosterone level remains within normal limits, because 
higher levels may negatively inﬂ  uence spermatogenesis. In 
addition, patients should be cautioned that a small number of 
patients have suffered a deterioration in semen quality with 
antiestrogen therapy. Therefore, frequent semen analysis is 
essential during follow-up (Gilbaugh and Lipshultz 1994). 
Side effects of clomiphene therapy are usually mild and 
occur in less than 5% of patients (Siddiq and Sigman 2002). 
They include nausea, headache, weight gain, alterations in 
libido, visual ﬁ  eld changes, dizziness, gynecomastia and 
allergic dermatitis.
Many well-designed prospective, randomized, con-
trolled studies of clomiphene citrate failed to identify 
any efﬁ  cacy over placebo (Foss et al 1973; Paulson 1979; 
Ronnberg 1980; Abel et al 1982; Sokol et al 1988). Only 
two studies revealed a positive effect on both sperm counts 
and pregnancy rates (Wang et al 1983; Check et al 1989). 
However, a multicenter WHO study of 190 couples ran-
domized to receive 25 mg clomiphene daily or placebo 
showed only an 8% pregnancy rate in the treatment arm 
(WHO 1992).
Tamoxifen citrate is an antiestrogen that exhibits less 
estrogenic activity than clomiphene citrate and has been 
used in the treatment of male infertility. Doses range from 
10 to 30 mg orally per day. Side effects are similar to those 
seen with clomiphene citrate but occur with lower frequency 
because of its weaker estrogenic properties. Although initial 
uncontrolled studies reported impressive results, including 
increased sperm densities and pregnancy rates (Vermeulen 
and Comhaire 1978; Bartsch and Scheiber 1981; Buvat et al 
1983), all controlled studies using tamoxifen 10 to 20 mg 
per day reported negative results (Willis et al 1977; AinMelk 
et al 1987; Krause et al 1992).
Many trials have reported improvements in all semen 
parameters and pregnancy rates with the use of antiestrogens 
in men with idiopathic infertility (Allag and Alexander 1979; 
Bartsch and Scheiber 1981; Wang et al 1983; Check et al 
1989). Given the conﬂ  icting data in well-controlled stud-
ies, meta-analyses have been performed to resolve these 
differing conclusions. Kamischke and Nieschlag performed 
a meta-analysis of antiestrogen therapy (clomiphene and 
tamoxifen) that included randomized, placebo-controlled 
trials, and they concluded that treatment with antiestro-
gens had no signiﬁ  cant inﬂ  uence on pregnancy rates in the 
459 patients analyzed (odds ratio, 1.33; 95% conﬁ  dence 
interval, 0.78–2.28) (Kamischke and Nieschlag 1999). More 
recently, a Cochrane database review assessed ten stud-
ies involving 738 men with idiopathic infertility in which 
antiestrogen therapy was administered for at least 3 months 
(Vandekerckhove et al 2000). Only 5 trials speciﬁ  ed the 
randomization protocol. In these studies, the overall analysis 
showed improved testosterone, but the pregnancy rate was 
no better than that of the controls.
Antiestrogens are reasonably inexpensive and safe oral 
medications for the treatment for idiopathic male infertility, 
which explains their popularity. Nevertheless, their efﬁ  cacy 
is in doubt, and prolonged courses of empirical antiestrogen Biologics: Targets & Therapy 2007:1(3) 266
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therapy should not be used as a substitute for more effective 
modes of management.
Aromatase inhibitors
The majority of estrogen production occurs within fat cells, 
where the enzyme aromatase converts circulating testoster-
one into estrogen. Hence, markedly obese men may have 
an excessive endogenous conversion of testosterone into 
estrogen. In theory, an alteration in the ratios of estrogen 
and testosterone systemically or within the testis could 
decrease pituitary levels of LH and FSH and impair sperm 
production (Kulin and Reiter 1972; Veldhuis et al 1985). 
Aromatase inhibitors block the conversion of testosterone to 
estrogen, thereby enhancing spermatogenesis (Ciaccio et al 
1978). Additionally, aromatase inhibitors block the inhibi-
tory feedback of testosterone on the hypothalamic pituitary 
gonadal axis by reducing the amount of testosterone that is 
converted to the more potent inhibitory signal, estrogen. In 
the testis, aromatase activity is primarily located in the Leydig 
and Sertoli cells (Inkster et al 1995).
Aromatase inhibitors are relatively expensive phar-
maceutical agents and may be steroidal (testolactoma) or 
nonsteroidal (anastrozole, letrozole and exemestane). Anas-
trazole represents the fourth generation of aromatase inhibi-
tors. Although highly potent and speciﬁ  c for the aromatase 
enzyme, it differs from earlier steroid-based inhibitors in that 
it is less likely to exhibit agonist or antagonist steroidal prop-
erties. The drug is safe and well-tolerated and can be admin-
istered orally in men with idiopathic oligozoospermia. One 
indication for treatment is an abnormal testosterone/estrogen 
ratio. However, normal ratio ranges have not yet been stan-
dardized. Serum testosterone, estrogen concentrations and 
seminal parameters are followed at regular intervals. In addi-
tion, serum liver function tests should be performed because 
transaminase elevations are common but tend to resolve after 
therapy is stopped (Siddiq and Sigman 2002).
In older studies, treatment with testosterone aromatase 
inhibitors produced conﬂ  icting results (Haidl and Schill 
1991). Most recently, it was shown that in men who are 
infertile with a low serum testosterone-to-estradiol ratio, 
treatment with the aromatase inhibitor testolactone 50 to 
100 mg twice daily signiﬁ  cantly increased sperm count 
and motility and corrected the hormonal abnormality 
(Pavlovich et al 2001; Raman and Schlegel 2002). Similar 
changes were seen after treatment with the more selective 
aromatase inhibitor anastrozole 1 mg/day (Raman and 
Schlegel 2002). Aromatase inhibitors may be useful in a 
subpopulation of subfertile men, especially in those with 
subnormal testosterone and high estradiol levels. However, 
the testosterone-to-estradiol ratio remains to be deﬁ  ned 
in men with normogonadotropic idiopathic infertility. 
Placebo-controlled, randomized studies are still needed 
to assess deﬁ  nitively the effect of aromatase inhibitors in 
patients with idiopathic male infertility.
Miscellaneous treatments
Many nonhormonal treatments for idiopathic infertility are 
currently being evaluated. Some nonhormonal therapies 
improve sperm quality by boosting the kallifrein-kinin sys-
tem or by interfering with the production of prostaglandins. 
Another growing area of interest centers on the use of anti-
oxidants to scavenge excessive seminal ROS, which may be 
causing direct spermatozoa damage.
A variety of vitamins, nutritional supplements and anti-
inﬂ  ammatory agents have been used in the empirical therapy 
of male infertility. Thyroxine, arginine, corticosteroids, anti-
biotics, zinc, methylxanthines, bromocriptine and vitamins 
A, E and C have all been shown to be of little or no beneﬁ  t 
in the treatment of male infertility without evidence of a 
speciﬁ  c deﬁ  ciency (Siddiq and Sigman 2002). Controlled 
studies of kallikrein, indomethacin and glutathione have 
produced varying results, none of which are sufﬁ  cient to 
encourage their use (Barkay et al 1984; Glezerman et al 
1993; Lenzi et al 1993).
L-Carnitine is a known component of epididymal secre-
tions and is now available as an over-the-counter nutritional 
supplement for the treatment of idiopathic male infertility. In 
human seminal ﬂ  uid, approximately 50% of total carnitine 
exists as acetyl-carnitine. The compound plays a critical role 
in intracellular energy metabolism as well as spermatozoa 
membrane stabilization. Carnitine also has an antioxidant 
capacity, and it protects sperm from oxidative damage 
(Agarwal and Said 2004). However, studies have not shown 
a direct relationship between semen L-carnitine levels and 
fertility or that orally administered carnitine increases lev-
els within the epididymis (Souﬁ  r et al 1984). Uncontrolled 
studies demonstrate improvement in semen parameters but 
not fertility (Costa et al 1994; Vitali et al 1995). Two recent 
randomized, controlled trials of carnitine and acetyl carnitine 
for idiopathic infertility (Lenzi et al 2003, 2004) reported 
statistically signiﬁ  cant improvements in seminal parameters, 
but they have certain drawbacks. Carnitine levels in semen 
did not change despite therapy. Reported pregnancy rates 
were only 8% (Lenzi et al 2003) and 13% (Lenzi et al 2004). 
Although improvements in the motile sperm count were sta-
tistically signiﬁ  cant, they may not be clinically relevant as it Biologics: Targets & Therapy 2007:1(3) 267
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was only 9 million per ml in the treated group and 7.4 million 
per ml in the controls. At this time, there is little evidence 
that carnitine therapy has any clinical beneﬁ  t. Thus, the use 
of carnitine supplementation in idiopathic male infertility 
remains questionable.
Take home message
Numerous advances have been made in reproductive medi-
cine in the last few years. Infertile couples who previously 
were considered untreatable now have a chance at genetic 
paternity. ART provide a great opportunity to families with 
infertility, and their used has become routine in the treat-
ment of infertile couples. The increasing use of ICSI as 
an efﬁ  cient therapy for cases of male infertility has become 
an applicable means to overcome multiple sperm deﬁ  ciencies. 
Even men with potentially treatable causes of infertility can 
be treated with ART instead of a speciﬁ  c therapy. However, 
the potential medical risks such as those of multiple-gestation 
pregnancies and the associated costs cannot be ignored. 
Primarily, speciﬁ  c therapeutic therapy directed against the 
etiological cause of infertility should be attempted. Speciﬁ  c 
medical management of infertility is based on identifying 
reversible causes of infertility and treating them with appro-
priate medications. However, if no speciﬁ  c etiology can be 
identiﬁ  ed, empiric therapy can be introduced in an attempt to 
improve semen parameters and subsequent fertility potential 
through natural intercourse. It is mandatory that a treatment 
timeline and endpoints be established prior to the initiation of 
empiric therapy. Many of the empiric therapies do hold poten-
tial beneﬁ  t, and as greater understanding is gained of what is 
now considered idiopathic infertility, a more speciﬁ  c applica-
tion of these therapies may yield more successful results.
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